Similarly, while it is known that Akt and ERK1/2 are activated by CXCL12 in CLL, the downstream targets of these pathways and activation of other pathways have not been elucidated [9]. This evidence concerns the gene MAPK3 and B-cell chronic lymphocytic leukemia.